The role of interleukin-6 in the expression of PD-1 and PDL-1 on central nervous system cells following infection with theiler's murine encephalomyelitis virus

Journal of Virology

Volumn 87, Issue 21, 2013, Pages 11538-11551

  Jin, Young Hee ^a   Hou, Wanqiu ^a,c   Kang, Hyun Seok ^a   Koh, Chang Sung ^b   Kim, Byung S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; INTERFERON RECEPTOR; INTERLEUKIN 6; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; RECOMBINANT INTERLEUKIN 6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CELL; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; IN VITRO STUDY; INFECTION RESISTANCE; INFECTION SENSITIVITY; KNOCKOUT MOUSE; MACROPHAGE; MICROGLIA; MURINE ENCEPHALOMYELITIS VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; UPREGULATION; VIRUS ENCEPHALITIS;

ANIMALS; ANTIGENS, CD274; CARDIOVIRUS INFECTIONS; CENTRAL NERVOUS SYSTEM; FEMALE; INTERLEUKIN-6; MACROPHAGES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROGLIA; PROGRAMMED CELL DEATH 1 RECEPTOR; THEILOVIRUS;

EID: 84886876625     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01967-13     Document Type: Article

References (47)

1. Theiler M. 1934. Spontaneous encephalomyelitis of mice-a new virus. Dis. Sci. 80:122.
2. Dal Canto MC, Kim BS, Miller SD, Melvold RW. 1996. Theiler's murine encephalomyelitis virus (TMEV)-induced demyelination: a model for human multiple sclerosis. Methods 10:453-461.
3. Kim BS, Lyman MA, Kang BS, Kang HK, Lee HG, Mohindru M, Palma JP. 2001. Pathogenesis of virus-induced immune-mediated demyelination. Immunol. Res. 24:121-130.
4. Rodriguez M, Leibowitz J, David CS. 1986. Susceptibility to Theiler's virus-induced demyelination. Mapping of the gene within the H-2D region. J. Exp. Med. 163:620-631.
5. Pullen LC, Park SH, Miller SD, Dal Canto MC, Kim BS. 1995. Treatment with bacterial LPS renders genetically resistant C57BL/6 mice susceptible to Theiler's virus-induced demyelinating disease. J. Immunol. 155:4497-4503.
6. Yamada M, Zurbriggen A, Fujinami RS. 1990. The relationship between viral RNA, myelin-specific mRNAs, and demyelination in central nervous system disease during Theiler's virus infection. Am. J. Pathol. 137:1467-1479.
7. Jin YH, Mohindru M, Kang MH, Fuller AC, Kang B, Gallo D, Kim BS. 2007. Differential virus replication, cytokine production, and antigenpresenting function by microglia from susceptible and resistant mice infected with Theiler's virus. J. Virol. 81:11690-11702.
8. Lyman MA, Myoung J, Mohindru M, Kim BS. 2004. Quantitative, not qualitative, differences in CD8(_) T cell responses to Theiler's murine encephalomyelitis virus between resistant C57BL/6 and susceptible SJL/J. mice. Eur. J. Immunol. 34:2730-2739.
9. Mohindru M, Kang B, Kim BS. 2006. Initial capsid-specific CD4(_) T cell responses protect against Theiler's murine encephalomyelitisvirusinduced demyelinating disease. Eur. J. Immunol. 36:2106-2115.
10. Kim BS, Palna JP. 1999. Immune mechanisms of Theiler's virus-induced demyelination. Exp. Mol. Med. 31:115-121.
11. Jin YH, Kang B, Kim BS. 2009. Theiler's virus infection induces a predominant pathogenic CD4_ T cell response to RNA polymerase in susceptible SJL/J. mice. J. Virol. 83:10981-10992.
12. Hou W, Kang HS, Kim BS. 2009. Th17 cells enhance viral persistence and inhibit T cell cytotoxicity in a model of chronic virus infection. J. Exp. Med. 206:313-328.
13. Crane MA, Yauch R, Dal Canto MC, Kim BS. 1993. Effect of immunization with Theiler's virus on the course of demyelinating disease. J. Neuroimmunol. 45:67-73.
14. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. 2008. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26:677-704.
15. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192:1027-1034.
16. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. 1999. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:141-151.
17. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, Honjo T. 2001. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291:319-322.
18. Iwai Y, Terawaki S, Ikegawa M, Okazaki T, Honjo T. 2003. PD-1 inhibits antiviral immunity at the effector phase in the liver. J. Exp. Med. 198:39-50.
19. Petrovas C, Casazza JP, Brenchley JM, Price DA, Gostick E, Adams WC, Precopio ML, Schacker T, Roederer M, Douek DC, Koup RA. 2006. PD-1 is a regulator of virus-specific CD8_ T cell survival in HIV infection. J. Exp. Med. 203:2281-2292.
20. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682-687.
21. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T. 1996. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8:765-772.
22. Terawaki S, Chikuma S, Shibayama S, Hayashi T, Yoshida T, Okazaki T, Honjo T. 2011. IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J. Immunol. 186:2772-2779.
23. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, Koulmanda M, Freeman GJ, Sayegh MH, Sharpe AH. 2006. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203:883-895.
24. Ishida M, Iwai Y, Tanaka Y, Okazaki T, Freeman GJ, Minato N, Honjo T. 2002. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol. Lett. 84:57-62.
25. Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K, Azuma M, Yagita H. 2002. Expression of programmed death 1 ligands by murine T cells and APC. J. Immunol. 169:5538-5545.
26. Duncan DS, Miller SD. 2011. CNS expression of B7-H1 regulates proinflammatory cytokine production and alters severity of Theiler's virusinduced demyelinating disease. PLoS One 6:e18548. doi:10.1371/journal.pone.0018548.
27. Suematsu S, Matsusaka T, Matsuda T, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T. 1992. Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 89:232-235.
28. Hou W, So EY, Kim BS. 2007. Role of dendritic cells in differential susceptibility to viral demyelinating disease. PLoS Pathog. 3:e124. doi:10.1371/journal.ppat.0030124.
29. Schreiner B, Mitsdoerffer M, Kieseier BC, Chen L, Hartung HP, Weller M, Wiendl H. 2004. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J. Neuroimmunol. 155:172-182.
30. Wiesemann E, Deb M, Trebst C, Hemmer B, Stangel M, Windhagen A. 2008. Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis. Mult. Scler. 14:166-176.
31. Jin YH, Hou W, Kim SJ, Fuller AC, Kang B, Goings G, Miller SD, Kim BS. 2010. Type I interferon signals control Theiler's virus infection site, cellular infiltration and T cell stimulation in the CNS. J. Neuroimmunol. 226:27-37.
32. Groschel S, Piggott KD, Vaglio A, Ma-Krupa W, Singh K, Goronzy JJ, Weyand CM. 2008. TLR-mediated induction of negative regulatory ligands on dendritic cells. J. Mol. Med. (Berl.) 86:443-455.
33. Lafon M, Megret F, Meuth SG, Simon O, Velandia Romero ML, Lafage M, Chen L, Alexopoulou L, Flavell RA, Prehaud C, Wiendl H. 2008. Detrimental contribution of the immuno-inhibitor B7-H1 to rabies virus encephalitis. J. Immunol. 180:7506-7515.
34. Jin YH, Kaneyama T, Kang MH, Kang HS, Koh CS, Kim BS. 2011. TLR3 signaling is either protective or pathogenic for the development of Theiler's virus-induced demyelinating disease depending on the time of viral infection. J. Neuroinflammation 8:178. doi:10.1186/1742-2094-8-178.
35. Jin YH, Kim SJ, So EY, Meng L, Colonna M, Kim BS. 2012. Melanoma differentiation-associated gene 5 is critical for protection against Theiler's virus-induced demyelinating disease. J. Virol. 86:1531-1543.
36. Kang DC, Gopalkrishnan RV, Lin L, Randolph A, Valerie K, Pestka S, Fisher PB. 2004. Expression analysis and genomic characterization of human melanoma differentiation associated gene-5, mda-5: a novel type I interferon-responsive apoptosis-inducing gene. Oncogene 23: 1789-1800.
37. Kang DC, Gopalkrishnan RV, Wu Q, Jankowsky E, Pyle AM, Fisher PB. 2002. mda-5: an interferon-inducible putative RNA helicase with doublestranded RNA-dependent ATPase activity and melanoma growthsuppressive properties. Proc. Natl. Acad. Sci. U. S. A. 99:637-642.
38. Phares TW, Ramakrishna C, Parra GI, Epstein A, Chen L, Atkinson R, Stohlman SA, Bergmann CC. 2009. Target-dependent B7-H1 regulation contributes to clearance of central nervous system infection and dampens morbidity. J. Immunol. 182:5430-5438.
39. Jeong HY, Lee YJ, Seo SK, Lee SW, Park SJ, Lee JN, Sohn HS, Yao S, Chen L, Choi I. 2008. Blocking of monocyte-associated B7-H1 (CD274) enhances HCV-specific T cell immunity in chronic hepatitis C infection. J. Leukoc. Biol. 83:755-764.
40. Said EA, Dupuy FP, Trautmann L, Zhang Y, Shi Y, El-Far M, Hill BJ, Noto A, Ancuta P, Peretz Y, Fonseca SG, Van Grevenynghe J, Boulassel MR, Bruneau J, Shoukry NH, Routy JP, Douek DC, Haddad EK, Sekaly RP. 2010. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4_ T cell activation during HIV infection. Nat. Med. 16:452-459.
41. Yao S, Wang S, Zhu Y, Luo L, Zhu G, Flies S, Xu H, RuffW, Broadwater M, Choi IH, Tamada K, Chen L. 2009. PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood 113: 5811-5818.
42. Sadagopal S, Lorey SL, Barnett L, Sutherland D, Basham R, Erdem H, Kalams SA, Haas DW. 2010. Enhanced PD-1 expression by T cells in cerebrospinal fluid does not reflect functional exhaustion during chronic human immunodeficiency virus type 1 infection. J. Virol. 84: 131-140.
43. Wolfle SJ, Strebovsky J, Bartz H, Sahr A, Arnold C, Kaiser C, Dalpke AH, Heeg K. 2011. PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur. J. Immunol. 41:413-424.
44. Palma JP, Kwon D, Clipstone NA, Kim BS. 2003. Infection with Theiler's murine encephalomyelitis virus directly induces proinflammatory cytokines in primary astrocytes via NF-kappaB activation: potential role for the initiation of demyelinating disease. J. Virol. 77:6322-6331.
45. Magnus T, Schreiner B, Korn T, Jack C, Guo H, Antel J, Ifergan I, Chen L, Bischof F, Bar-Or A, Wiendl H. 2005. Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS. J. Neurosci. 25:2537-2546.
46. So EY, Kang MH, Kim BS. 2006. Induction of chemokine and cytokine genes in astrocytes following infection with Theiler's murine encephalomyelitis virus is mediated by the Toll-like receptor 3. Glia 53: 858-867.
47. So EY, Kim BS. 2009. Theiler's virus infection induces TLR3-dependent upregulation of TLR2 critical for proinflammatory cytokine production. Glia 57:1216-1226.